disomisation

Disomisation is a process used in the pharmaceutical industry to convert a racemic mixture of a drug into its pure enantiomer form. A racemic mixture is a 1:1 combination of two enantiomers, which are mirror-image versions of each other. Disomisation involves the selective removal of one enantiomer from the mixture, resulting in a product that contains only the desired enantiomer.

The process of disomisation typically involves the use of a chiral resolving agent, which is a substance that can distinguish between the two enantiomers and selectively bind to one of them. The resolving agent is then separated from the desired enantiomer, leaving behind the pure enantiomer form of the drug.

Disomisation is an important process in the pharmaceutical industry because many drugs are chiral, meaning they have a specific three-dimensional structure that determines their biological activity. The two enantiomers of a chiral drug can have different effects on the body, with one being the active form and the other being inactive or even harmful. By using disomisation, pharmaceutical companies can produce drugs that are more effective and safer for patients.

The disomisation process can be time-consuming and expensive, as it requires the use of specialized equipment and techniques. However, the resulting pure enantiomer form of the drug can have significant benefits for patients, making disomisation an important tool in the development of new medications.